Stiripentol seems to be a useful option in the treatment of patients with severely pharmacoresistant epilepsy.
The COVID-19 pandemic presents unique challenges to PWE, including increased seizure rates, problems with access and cost of life-saving medications.
The present study revealed acceptance of disability as an important psychological concept, in addition to social support and depression as previously reported, to improve the quality of life of patients with epilepsy.
Seizures can happen in patients with COVID-19 critical illness, even those without any prior neurologic history, and that they are associated with worse outcomes.
Employment status and seizure control, but not location of surgery, significantly predicted quality of life.
Complete resection of the MRI lesion is the most important factor to maintain long-term seizure freedom.
Safe and effective antiepileptic drugs as alternatives to valproate are the need of the hour.
Status epilepticus can be a neurological manifestation of SARS-CoV-2 (COVID-19) infection. Systemic inflammatory syndrome due to cytokine release could play a role in COVID-19-related SE.
Some 134 proteins were significantly changed in both the hippocampus and frontal cortex, the front third of the brain, which is also responsible for controlling thought and body movements.
